Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Trifluridine-tipiracil
63%
Dosing Schedule
58%
TAS-102
47%
Anticholinergic Risk Scale
45%
Severe Neutropenia
40%
Pairwise Meta-analysis
38%
Bevacizumab
36%
Confidence Interval
36%
Weekly Dosing
35%
Neutropenia
35%
Hematotoxicity
35%
Advanced Colorectal Cancer
32%
Recurrent Colorectal Cancer
32%
Renal Function
32%
Major Depressive Disorder
31%
Meta-analysis
31%
Japanese Adverse Drug Event Report (JADER)
29%
Newer Antidepressants
29%
Systematic Meta-analysis
29%
Nontuberculous Mycobacterial Lung Disease
29%
Secondary Pulmonary Hypertension
29%
Nontuberculous Mycobacteriosis
29%
Intermittent theta Burst Stimulation (iTBS)
29%
Japanese Adults
29%
Colorectal Cancer
29%
Febrile Neutropenia
29%
Cancer Chemotherapy
29%
Drug Use
29%
Nonhematologic
29%
Anti-PD-1 Antibody
29%
L-OHP
29%
Metastatic Colorectal Cancer (mCRC)
29%
Creatinine Clearance
29%
Emetogenicity
29%
Hematopoietic Function
29%
Serum IgG Level
29%
Relapsed Lymphoma
29%
CBDCA
29%
R-CHOP Therapy
29%
Combination of Therapies
29%
System Restoration
29%
Early Palliative Care
29%
Fosaprepitant
29%
Aprepitant
29%
Pharmaceutical Consultation
29%
Immune Checkpoint Inhibitors
29%
Multidisciplinary Cancer Team
29%
Cancer-associated Thrombosis
29%
Vicarious Experience
29%
Reporting Odds Ratio
25%
Left DLPFC
24%
MFOLFOX6
20%
Japanese Patients
19%
Standardized Mean Difference
19%
Nausea
19%
Diarrhea
19%
Vomiting
19%
Safety Signal
16%
Palliative Care Interventions
16%
Calvert Formula
16%
Diffuse Lung Disease
14%
Ground Grass Opacity
14%
Right Dorsolateral Prefrontal Cortex
14%
Depressive Symptoms
14%
TCR-T Therapy
14%
High Incidence
13%
Visual Infusion Phlebitis Score
12%
Vascular Pain
12%
Thrombocytopaenia
12%
Overall Survival
11%
Fibrocavitary
11%
Treatment Failure
11%
Day off
11%
Bacterial Cultivation
11%
Mycobacterium
11%
Residual Lesions
11%
Random Effects
9%
Mean Risk
9%
Randomized Placebo-controlled Trial
9%
Placebo
9%
Cancer of Unknown Primary
9%
Antidepressants
9%
Method Parameters
9%
Stimulation Protocol
9%
Lymphocyte Count
9%
Ribosomal Protein Genes
9%
R-CHOP-14
9%
Absolute Reticulocyte Count
9%
R-CHOP-21
9%
CD20+
9%
Delayed Vomiting
9%
Risk Ratio
9%
Symptom Scale
9%
Appropriate Treatment
9%
Japan
9%
Anticholinergic Burden
8%
Risk Score
8%
Pleural Thymoma
8%
70 Years Old
8%
Anemia
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Adverse Event
93%
Colorectal Carcinoma
87%
Tipiracil Plus Trifluridine
74%
Chemotherapy
67%
Retrospective Study
62%
Combination Therapy
62%
Cholinergic Receptor Blocking Agent
58%
Carboplatin
58%
Neutropenia
51%
Chemotherapy Induced Nausea and Vomiting
50%
Immune Checkpoint Inhibitor
42%
Tipiracil
41%
Trifluridine
41%
Nausea and Vomiting
38%
Bevacizumab
35%
Thrombocytopenia
34%
Dexamethasone
33%
Cohort Study
32%
Oxaliplatin
31%
Adverse Drug Reaction
31%
Remission
29%
Headache
29%
Abdominal Cancer
29%
Febrile Neutropenia
29%
Ifosfamide
29%
Rituximab
29%
Metastatic Colorectal Cancer
29%
Cancer Chemotherapy
29%
Olanzapine
29%
Colorectal Cancer
29%
Blood Toxicity
29%
Non Small Cell Lung Cancer
29%
Erlotinib
29%
Gemcitabine
29%
Cisplatin
29%
Meglumine
29%
Aprepitant
29%
Fosaprepitant
29%
Liver Dysfunction
29%
Nonhodgkin Lymphoma
29%
Etoposide
29%
Allergic Reaction
29%
Creatinine
29%
Bilirubin
29%
Overall Survival
23%
Nausea
22%
Diarrhea
19%
Randomized Controlled Trial
14%
Random Effects Model
14%
Major Depression
14%
Phlebitis
12%
Antiemetic Agent
10%
Skin Disease
9%
Mycobacteria
9%
Cancer of Unknown Primary Site
9%
Ribosome Protein
9%
Neoplasm
8%
Epileptic Absence
8%
Thymoma
8%
Somnolence
8%
Pharmacotherapy
7%
Anticarcinogen
7%
Neurokinin 1 Receptor Antagonist
7%
Anemia
6%
Nivolumab
5%